Braveheart Bio (BRVE) 10% Owner Erez Chimovits Receives 30,000-Share Award

What Happened

• Erez Chimovits, reported as a 10% owner of Braveheart Bio (BRVE), received a derivative award on 2026-08-05 covering 30,000 shares. The filing lists the acquisition price as $0.00, indicating an award/option rather than a cash purchase. This is an award grant (reporting code A), not an immediate open‑market buy or sale.

Key Details

• Transaction date: August 5, 2026; Form 4 filed August 7, 2026 (appears timely).
• Award: 30,000 shares (derivative) at $0.00.
• Vesting: The underlying shares will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the issuer’s next annual meeting of stockholders, subject to continued service (Footnote F1).
• Transfer agreement: Chimovits has an agreement requiring transfer of any securities or economic benefit from these awards to OrbiMed Advisors LLC, which will provide them to OrbiMed Private Investments IX, LP (Footnote F2).
• Shares owned after transaction: not specified in the filing.

Context

• This filing documents a grant of a derivative award (stock option/award) that only becomes actual shares if and when it vests; it is not an immediate purchase or sale. Because Chimovits is a 10% owner and has an agreement with OrbiMed, the economic benefit is slated to go to a private investment fund rather than representing a personal market purchase.